TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cullinan Management ( (CGEM) ) has issued an announcement.
On December 8, 2025, Cullinan Therapeutics presented updated clinical data from its Phase 1 study of CLN-049 at the 67th American Society of Hematology Annual Meeting. The study, involving patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, showed promising efficacy and safety results, with notable complete response rates and durability in heavily pretreated patients. CLN-049, a novel FLT3xCD3 bispecific T cell engager, demonstrated potential as a new treatment option, particularly for patients with high-risk genetic features. The development of CLN-049 will continue under the FDA’s Fast Track designation, with further dose escalation and expansion cohorts planned for early 2026.
The most recent analyst rating on (CGEM) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Cullinan Management stock, see the CGEM Stock Forecast page.
Spark’s Take on CGEM Stock
According to Spark, TipRanks’ AI Analyst, CGEM is a Underperform.
Cullinan Management’s stock is facing significant challenges primarily due to its weak financial performance, characterized by persistent losses and negative cash flow. The technical analysis provides some short-term optimism, but the overall technical outlook remains bearish. The valuation is unattractive due to a negative P/E ratio and no dividend yield, indicating high risk for investors. The stock’s potential is heavily reliant on strategic changes and improved financial health.
To see Spark’s full report on CGEM stock, click here.
More about Cullinan Management
Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing potential first- or best-in-class therapies for autoimmune diseases and cancer. The company leverages expertise in T cell engagers, particularly in oncology, to advance its clinical-stage pipeline and deliver new standards of care.
Average Trading Volume: 1,153,154
Technical Sentiment Signal: Hold
Current Market Cap: $625.6M
Find detailed analytics on CGEM stock on TipRanks’ Stock Analysis page.